ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -41 مورد

Trials on lymph node management in cutaneous melanoma: MSLT-I, MSLT-II, DeCOG

Trials on lymph node management in cutaneous melanoma: MSLT-I, MSLT-II, DeCOG
Trial Population N Design Results
MSLT-I[1] Primary melanoma, clinically node negative 2001 Randomized to wide excision alone or wide excision with SLN biopsy and completion dissection for positive SLN
  • SLN strong prognostic indication
  • No significant melanoma-specific survival benefit, but intermediate-thickness node positive patients with better MSS
  • Improved RFS for SLN group
MSLT-II[2] Patients with SLN metastases 1939 Randomized to completion dissection or nodal observation
  • No difference in MSS
  • More complete staging with CLND
  • Slight improvement in DFS with CLND
DeCOG-SLT[3,4] Patients with SLN metastases 483 Randomized to completion dissection or nodal observation
  • No difference in MSS or DFS
CLND: completion lymph node dissection; DFS: disease-free survival; MSS: melanoma-specific survival; RFS: recurrence-free survival; SLN: sentinel lymph node.
References:
  1. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014; 370:599.
  2. Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017; 376:2211.
  3. Leiter U, Stadler R, Mauch C, et al. Final analysis of DeCOG-SLT trial: No survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol 2019; 37:3000.
  4. Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): A multicentre, randomised, phase 3 trial. Lancet Oncol 2016; 17:757.
Graphic 134491 Version 1.0